ASX · CSL.AX
CSL Limited
A$200.73+A$3.23 (+1.64%)
CSL Limited’s quoted price sits in the upper half of its reported 52-week range, 0.69% below the high.
Loading market information…
ASX · SPL.AX · AUD
Stock price, earnings
Quote as of Oct 30, 2026, 05:10 AM UTC. Cached market data; not a live quote.
One-year closing-price history · AUD. Historical prices are not a forecast.
Starpharma Holdings Limited’s quoted price sits in the lower half of its reported 52-week range, 48.57% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Starpharma Holdings Limited’s next earnings report is currently expected on Mar 2, 2027. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Starpharma Holdings Limited’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Starpharma Holdings Limited is a biopharmaceutical enterprise focused on the research, development, and global commercialization of dendrimer-based products for the pharmaceutical, life sciences, and other industries. Its current offerings include VivaGel, a non-antibiotic treatment and preventative measure for bacterial vaginosis. The company also provides the antiviral VivaGel condom and VIRALEZE, an antiviral nasal spray. Furthermore, Starpharma is actively progressing its DEP (dendrimer drug delivery) technology platform. This platform supports multiple oncology candidates in clinical development, such as DEP docetaxel (Phase 2), DEP cabazitaxel (Phase 2), DEP gemcitabine (Phase 1/2), and DEP irinotecan (Phase 2), all aimed at treating cancer. The DEP technology is also being applied to radiotheranostics for cancer diagnosis and therapy, Antibody Drug Conjugates (including DEP HER-2 ADC), and non-oncology programs. Additionally, DEP AZD0466 is currently in Phase 1/2 clinical trials for haematological malignancies. Founded in 1996, the company maintains its headquarters in Abbotsford, Australia.
Latest available per-share figures in AUD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 09:33 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Feb 27, 2023 |
| -A$0.02 |
| A$1.61M-82.14% vs estimate |
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
A$200.73+A$3.23 (+1.64%)
CSL Limited’s quoted price sits in the upper half of its reported 52-week range, 0.69% below the high.
A$2.73+A$0.01 (+0.37%)
Sigma Healthcare Limited’s quoted price sits in the lower half of its reported 52-week range, 14.69% below the high.
A$196.20-A$0.89 (-0.45%)
Pro Medicus Limited’s quoted price sits in the upper half of its reported 52-week range, 28.09% below the high.
A$55.60+A$0.68 (+1.24%)
Ramsay Health Care Limited’s quoted price sits in the upper half of its reported 52-week range, 0.89% below the high.
A$19.57+A$0.50 (+2.62%)
Sonic Healthcare Limited’s quoted price sits in the lower half of its reported 52-week range, 19.37% below the high.
A$143.64+A$1.44 (+1.01%)
Cochlear Limited’s quoted price sits in the lower half of its reported 52-week range, 50.67% below the high.
A$45.44+A$0.32 (+0.71%)
Ansell Limited’s quoted price sits in the upper half of its reported 52-week range, 2.84% below the high.
A$13.13-A$0.35 (-2.6%)
Telix Pharmaceuticals Limited’s quoted price sits in the lower half of its reported 52-week range, 27.94% below the high.
